CAR-T Cell Therapy Pipeline Shows Strong Momentum as 180+ Pharma Companies in the Race | DelveInsight

DelveInsight's "CAR T-Cell Therapy Pipeline Insight 2026" report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in the CAR T-Cell Therapy pipeline landscape. It covers the CAR T-Cell Therapy Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the CAR T-Cell Therapy Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the CAR T-Cell Therapy Pipeline? @ https://www.delveinsight.com/sample-request/chimeric-antigen-receptor-t-cell-therapy-car-t-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the CAR T-Cell Therapy Pipeline Report
• On July 24, 2026- Kyverna Therapeutics initiated a phase 2 Study of KYV-101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Treatment Refractory Stiff Person Syndrome. CAR-T therapy such as KYV-101 may be an effective treatment for SPS, by targeting these autoreactive B cells. Using chimeric antigen receptor (CAR) T-cell technology, engineered T cells with receptors are designed to recognize and eliminate B cells, including those that produce GAD autoantibodies.
• On July 23, 2026- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company conducted a phase 3 study is to compare the efficacy and safety of arlo-cel (BMS-986393) versus standard regimens in adult participants with Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma.
• On July 22, 2026- Cabaletta Bio highlighted a phase 1/2 study is being conducted to evaluate the safety and efficacy of an investigational therapy, CABA-201, a CD19-CAR T cell therapy, that can be given to patients with SSc who have active disease. A single dose of CABA-201 in combination with cyclophosphamide (CY) and fludarabine (FLU) will be evaluated.
• DelveInsight's CAR T-Cell Therapy Pipeline report depicts a robust space with 180+ active players working to develop 200+ pipeline therapies for CAR T-Cell Therapy treatment.
• The leading CAR T-Cell Therapy Companies such as Cartesian Therapeutics, Arcellx, Inc, Nexcella, Inc, Autolus Therapeutics, Sana Biotechnology, Orgenesis, CARsgen, TILT Biotherapeutics, Poseida Therapeutics, Precision BioSciences, Novartis, Kyverna Therapeutics, Cemacabtagene ansegedleucel, Hrain Biotechnology, UTC Therapeutics, Kiromic, Suzhou Fundamenta Therapeutics, Gracell Biotechnology, CARsgen, Innovent Biologics/Nanjing IASO Biotherapeutics, CellabMED, Umoja Biopharma, TC BioPharm, ElevateBio, Century Therapeutics and others.
• Promising CAR T-Cell Therapy Therapies such as Itacitinib, Cyclophosphamide, Fludarabine, WU-CART-007, Cevostamab, JNJ-68284528, Lenalidomide, Daratumumab, KYV-101, Epcoritamab, and others.

Want to know which companies are leading innovation in CAR T-Cell Therapy? @ https://www.delveinsight.com/sample-request/chimeric-antigen-receptor-t-cell-therapy-car-t-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

The CAR T-Cell Therapy Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The CAR T-Cell Therapy Pipeline Report also highlights the unmet needs with respect to the CAR T-Cell Therapy.

CAR T-Cell Therapy Overview
CAR T-cells are the fusion proteins of a selected single-chain fragment variable from a specific monoclonal antibody and one or more T-cell receptor intracellular signaling domains. A CAR combines antigen-binding domains-most commonly, a single-chain variable fragment (scFv) derived from the variable domains of antibodies with the signalling domains of the TCR chain and additional costimulatory domains from receptors, such as CD28, OX40, and CD137. CAR T cells may not only eradicate all cancer cells in the body, but they may remain in the body months after the infusion.

CAR T-Cell Therapy Emerging Drugs Profile
• Descartes-08: Cartesian Therapeutics
Descartes-08 is an mRNA-modified, autologous CAR T-cell product directed against B-Cell Maturation Antigen (BCMA) that utilizes a novel modality and mechanism of action for treating gMG and other autoimmune diseases. Descartes-08 differs from anti-B-cell agents, which do not address long-lived plasma cells, and differs from FcRn blockers or complement inhibitors, which attempt to intervene only after autoantibodies are produced and pathogenic mediators are amplified. Descartes-08 is intended to halt production of autoantibodies by targeting pathogenic long-lived plasma cells with the potential to survive for decades within the body. Currently, the drug is in the Phase II stage of its development for the treatment of Myasthenia gravis (gMG).

• CART-ddBCMA: Arcellx, Inc
CART-ddBCMA is a genetically modified cell therapy utilizing a novel synthetic binding domain that is computationally designed, highly stable, and engineered to reduce immunogenicity. CART-ddBCMA is a Phase I study of Arcellx's BCMA-specific CAR-modified T-cell therapy utilizing the company's novel BCMA-targeting binding domain for the treatment of patients with relapsed and refractory multiple myeloma. The Arcellx ddBCMA cell therapy has been granted Fast Track Designation and Orphan Drug Designation by the U.S. Food and Drug Administration. The Phase I study is currently enrolling patients. CART-ddBCMA was well tolerated and rapid, deep, and durable responses were observed at the first dose level of 100 million cells, with six of six evaluable patients responding per IMWG criteria. Currently, the drug is in the Phase II stage of its development for the treatment of Multiple myeloma.

• NXC-201: Nexcella, Inc
NXC-201 (formerly HBI0101) is a BCMA-targeted investigational chimeric antigen receptor T (CAR-T) cell therapy that is being studied in a comprehensive clinical development program for the treatment of patients with relapsed or refractory multiple myeloma and AL amyloidosis. NXC-201 (formerly HBI0101) is the only "Single-Day CRS" CAR-T cell therapy that is uniquely suited to target AL Amyloidosis and other autoimmune diseases. It is being studied in a comprehensive clinical development program for the treatment of patients with relapsed/refractory AL amyloidosis, and expanding into other autoimmune indications. These trials build on a robust NXC-201 clinical dataset initiated in February 2021. NXC-201 has been awarded Orphan Drug Designation (ODD) by the FDA in both AL Amyloidosis and multiple myeloma, and awarded EU ODD by the EMA in AL Amyloidosis. Currently, the drug is in the Phase I/II stage of its development for the treatment of AL Amyloidosis and multiple myeloma.

• AUTO-8: Autolus Therapeutics
AUTO8 is the next-generation product candidate for multiple myeloma which comprises two independent CARs for the multiple myeloma targets, BCMA and CD19. The company have developed an optimized BCMA CAR which is designed for improved killing of target cell that express BCMA at low levels. This has been combined with fast off rate CD19 CAR from obe-cel the company believes that the design of AUTO8 has the potential to induce deep and durable responses and extend the durability of effect over other BCMA CARs currently in development. Currently, the drug is in the Phase I stage of its development for the treatment of multiple myeloma.

• SG299: Sana Biotechnology
SG299, is the first drug candidate from the fusogen platform, in generating CD19-directed CAR T cells with in vivo delivery. In 2023, look forward to initial clinical data for SC291, allogeneic CAR T cells for patients with B cell cancers; filing an IND for SC262, allogeneic CAR T cells for patients that have failed previous CAR T therapy and filing an IND for SG299, in vivo CAR delivery program for patients with B cell cancers. Currently, the drug is in the Preclinical stage of its development for the treatment of chronic lymphocytic leukemia.

If you're tracking ongoing CAR T-Cell Therapy Clinical trials @ https://www.delveinsight.com/sample-request/chimeric-antigen-receptor-t-cell-therapy-car-t-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

The CAR T-Cell Therapy Pipeline report provides insights into:-
• The report provides detailed insights about companies that are developing therapies for the treatment of CAR T-Cell Therapy with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for CAR T-Cell Therapy Treatment.
• CAR T-Cell Therapy Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• CAR T-Cell Therapy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the CAR T-Cell Therapy market.

CAR T-Cell Therapy Companies
Cartesian Therapeutics, Arcellx, Inc, Nexcella, Inc, Autolus Therapeutics, Sana Biotechnology, Orgenesis, CARsgen, TILT Biotherapeutics, Poseida Therapeutics, Precision BioSciences, Novartis, Kyverna Therapeutics, Cemacabtagene ansegedleucel, Hrain Biotechnology, UTC Therapeutics, Kiromic, Suzhou Fundamenta Therapeutics, Gracell Biotechnology, CARsgen, Innovent Biologics/Nanjing IASO Biotherapeutics, CellabMED, Umoja Biopharma, TC BioPharm, ElevateBio, Century Therapeutics and others.

CAR T-Cell Therapy Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

CAR T-Cell Therapy Products have been categorized under various Molecule types such as,
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

From emerging drug candidates to competitive intelligence, the CAR T-Cell Therapy Pipeline Report @ https://www.delveinsight.com/sample-request/chimeric-antigen-receptor-t-cell-therapy-car-t-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the CAR T-Cell Therapy Pipeline Report
• Coverage- Global
• CAR T-Cell Therapy Companies- Cartesian Therapeutics, Arcellx, Inc, Nexcella, Inc, Autolus Therapeutics, Sana Biotechnology, Orgenesis, CARsgen, TILT Biotherapeutics, Poseida Therapeutics, Precision BioSciences, Novartis, Kyverna Therapeutics, Cemacabtagene ansegedleucel, Hrain Biotechnology, UTC Therapeutics, Kiromic, Suzhou Fundamenta Therapeutics, Gracell Biotechnology, CARsgen, Innovent Biologics/Nanjing IASO Biotherapeutics, CellabMED, Umoja Biopharma, TC BioPharm, ElevateBio, Century Therapeutics and others.
• CAR T-Cell Therapy Therapies- Itacitinib, Cyclophosphamide, Fludarabine, WU-CART-007, Cevostamab, JNJ-68284528, Lenalidomide, Daratumumab, KYV-101, Epcoritamab, and others.
• CAR T-Cell Therapy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• CAR T-Cell Therapy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Discover what's next for the CAR T-Cell Therapy Treatment landscape in this detailed analysis @- https://www.delveinsight.com/sample-request/chimeric-antigen-receptor-t-cell-therapy-car-t-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Introduction
2. Executive Summary
3. Chimeric Antigen Receptor T-Cell Therapy (CAR-T) : Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Chimeric Antigen Receptor T-Cell Therapy (CAR-T) - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug name: Company Name
9. Drug profiles in the detailed report.....
10. Mid Stage Products (Phase II)
11. Descartes-08: Cartesian Therapeutics
12. Drug profiles in the detailed report.....
13. Early Stage Products (Phase I/II)
14. NXC-201: Nexcella, Inc
15. Drug profiles in the detailed report.....
16. Preclinical and Discovery Stage Products
17. SG299: Sana Biotechnology
18. Drug profiles in the detailed report.....
19. Inactive Products
20. Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Key Companies
21. Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Key Products
22. Chimeric Antigen Receptor T-Cell Therapy (CAR-T) - Unmet Needs
23. Chimeric Antigen Receptor T-Cell Therapy (CAR-T) - Market Drivers and Barriers
24. Chimeric Antigen Receptor T-Cell Therapy (CAR-T) - Future Perspectives and Conclusion
25. Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Analyst Views
26. Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com

This release was published on openPR.